The goal of this program is to develop safe and effective topical antimicrobial agents for intravaginal use that will block sexual and perinatal transmission of viral and bacterial pathogens. Focusing on human primary cell cultures, Project 1 will evaluate candidate compounds that block human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus types 1 and 2 (HSV-1 and HSV- 2) infection. Although cell tropism for HSV and HIV is quite different and both viruses bind unique receptors and co-receptors during the processes of attachment and penetration, both interact with a common cell surface component, heparan sulfate (HS) glycosaminoglycans (GAGs). Similarly, the bacterial STD pathogens, Chlamydia trachomatis and N. gonorrhoeae, which are the focus of studies in Project 2, interact with HS GAGs during bacterial invasion. The binding of microbes to cell surface HS can be competitively blocked by sulfated polysaccharides (SPS). We have successfully identified several SPS or sulfated polymers that inhibit HSV and HIV-1 infection and exhibit little or no cytotoxicity. In further studies, we will more extensively evaluate this class of compounds. This will involve defining the HS sequence required for HSV invasion of cells of the human female genital tract as this receptor is the target for this class of candidate antimicrobials. We will also evaluate novel classes of candidate antimicrobials which may block other steps in viral pathogenesis. Because compounds cannot be optimally evaluated using cell lines, which are transformed and differ markedly from in vivo conditions, we have established primary cell culture systems for evaluation of candidate compounds. Using these model culture systems, we propose to further evaluate SPS and related compounds, identify new compounds, and determine how these agents inhibit viral pathogens. Knowledge gained about the mechanism of antiviral activity will facilitate the selection of rational combinations of compounds with enhanced potency or limited toxicities. Taken together, results of these studies should lead to identification of promising novel agents for topical formulation for intravaginal use to prevent STDs.

Project Start
2001-09-01
Project End
2002-08-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
$180,480
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Anderson, Robert A; Feathergill, Kenneth A; Chany 2nd, Calvin J et al. (2009) Nitric oxide-dependent human acrosomal loss induced by PPCM (SAMMA) and by nitric oxide donors occurs by independent pathways: basis for synthesis of an improved contraceptive microbicide. J Androl 30:168-82
Milligan, Gregg N; Young, Christal G; Meador, Michael G et al. (2005) Effects of candidate vaginally-applied microbicide compounds on innate immune cells. J Reprod Immunol 66:103-16
Rupp, Richard; Rosenthal, Susan L; Stanberry, Lawrence R (2005) Pediatrics and herpes simplex virus vaccines. Semin Pediatr Infect Dis 16:31-7
Bourne, Nigel; Stegall, Rachael; Montano, Raquel et al. (2005) Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother 49:1181-3
Keller, Marla J; Tuyama, Ana; Carlucci, Maria Josefina et al. (2005) Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 55:420-3
John, Minnie; Keller, Marla J; Fam, Ehsan H et al. (2005) Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 192:1731-40
Anderson, Robert A; Feathergill, Kenneth; Diao, Xiao-Hui et al. (2004) Contraception by Ushercell (cellulose sulfate) in formulation: duration of effect and dose effectiveness. Contraception 70:415-22
Rupp, Richard; Stanberry, Lawrence R; Rosenthal, Susan L (2004) New biomedical approaches for sexually transmitted infection prevention: vaccines and microbicides. Adolesc Med Clin 15:393-407
Stanberry, Lawrence R; Rosenthal, Susan L; Mills, Lisa et al. (2004) Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis 39:1433-8
Milligan, Gregg N; Chu, Chin-Fun; Young, Christal G et al. (2004) Effect of candidate vaginally-applied microbicide compounds on recognition of antigen by CD4+ and CD8+ T lymphocytes. Biol Reprod 71:1638-45

Showing the most recent 10 out of 40 publications